Literature DB >> 30205158

Histopathological and microbiological findings and diagnostic performance of GeneXpert in clinically suspected tuberculous lymphadenitis.

Samreen Sarfaraz1, Sundus Iftikhar2, Yousuf Memon3, Naila Zahir4, Fivzia Farooq Hereker5, Naseem Salahuddin6.   

Abstract

OBJECTIVES: The primary objective was to determine the association between histopathological and microbiological findings in patients clinically suspected to have tuberculous lymphadenitis. A secondary objective was to assess the diagnostic utility of GeneXpert in lymph node specimens.
METHOD: This was a single-centre prospective cohort study, performed in the Infectious Disease Clinic at The Indus Hospital. Three hundred and forty-one adult patients with chronically enlarged, accessible lymph nodes were enrolled after obtaining verbal consent, between February 2013 and April 2016. Tissue specimens were processed for histopathology, acid-fast bacillus (AFB) microscopy, AFB culture, and GeneXpert. Based on these results, anti-tuberculosis therapy (ATT) was prescribed. Clinical characteristics and treatment outcomes were recorded.
RESULTS: There were 297 evaluable patients; 74.4% were diagnosed with tuberculous lymphadenitis (TBLA), 6.7% with a malignancy, and 12.8% with reactive nodes. TBLA was diagnosed on suggestive histopathology in 89.6% of cases, followed by GeneXpert (32.6%), mycobacterial culture (26.6%), and AFB smear positivity (12.5%). The sensitivity of GeneXpert was 65.7% when assessed against AFB culture. Drug resistance was displayed by 8.2% of GeneXpert-positive cases and 11.7% of culture-positive cases. The majority of TBLA patients (88.7%) responded favorably to ATT.
CONCLUSIONS: In light of laboratory evidence, a quarter of patients suspected of TBLA had an alternative diagnosis, highlighting its importance in avoiding over-treatment and diagnostic delays in malignancy. Although sensitivity is poor, the demonstration of drug resistance by both GeneXpert and AFB culture represents a useful tool to guide treatment.
Copyright © 2018. Published by Elsevier Ltd.

Entities:  

Keywords:  Chronic granulomatous inflammation; GeneXpert; Malignancy; Mycobacterial culture; Reactive nodes

Mesh:

Substances:

Year:  2018        PMID: 30205158     DOI: 10.1016/j.ijid.2018.08.020

Source DB:  PubMed          Journal:  Int J Infect Dis        ISSN: 1201-9712            Impact factor:   3.623


  6 in total

1.  Xpert MTB/RIF Ultra and Xpert MTB/RIF assays for extrapulmonary tuberculosis and rifampicin resistance in adults.

Authors:  Mikashmi Kohli; Ian Schiller; Nandini Dendukuri; Mandy Yao; Keertan Dheda; Claudia M Denkinger; Samuel G Schumacher; Karen R Steingart
Journal:  Cochrane Database Syst Rev       Date:  2021-01-15

2.  The value of histological examination in the diagnosis of tuberculous lymphadenitis in the era of rapid molecular diagnosis.

Authors:  Sabira Tahseen; Atiqa Ambreen; Sheeba Ishtiaq; Faisal M Khanzada; Nauman Safdar; Lisbet Sviland; Tehmina Mustafa
Journal:  Sci Rep       Date:  2022-05-27       Impact factor: 4.996

3.  Evaluation of Xpert MTB/RIF for the Diagnosis of Lymphatic Tuberculosis.

Authors:  Hou-He Li; Zhi-Jian He; Jia-Qi Liang; Gui-Lin Li; Tian-Ao Xie; Ye-Ling Liu; Zhong-Wei Li; Xuan-Cheng Feng; Yong Xia; Xu-Guang Guo
Journal:  Biomed Res Int       Date:  2020-06-28       Impact factor: 3.411

4.  Frequency, clinical characteristics, risks, and outcomes of Paradoxical upgrading reactions during anti-tuberculosis treatment in tuberculous lymphadenitis.

Authors:  Samreen Sarfaraz; Sundus Iftikhar; Naseem Salahuddin
Journal:  Pak J Med Sci       Date:  2020-01       Impact factor: 1.088

5.  Integration of cytopathology with molecular tests to improve the lab diagnosis for TBLN suspected patients.

Authors:  Abay Atnafu; Kassu Desta; Selfu Girma; Dawit Hailu; Gebeyehu Assefa; Shambel Araya; Dinksira Bekele; Liya Wassie; Kidist Bobosha
Journal:  PLoS One       Date:  2022-03-31       Impact factor: 3.240

6.  Investigation of Granulomatous Inflammations in Terms of Tuberculosis Diagnosis: A 5-Year Multi-center Laboratory Study.

Authors:  Derya Öztomurcuk; Özlem Terzi; Canan Demirci; Zeki Kılıçaslan
Journal:  Turk Thorac J       Date:  2022-01
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.